Kazia Therapeutics Ltd (ASX:KZA) insider Steven Coffey acquired 60,000 shares of the firm’s stock in a transaction dated Wednesday, July 3rd. The shares were purchased at an average cost of A$0.33 ($0.23) per share, with a total value of A$19,860.00 ($14,085.11).
Kazia Therapeutics stock opened at A$0.41 ($0.29) on Friday. The stock has a market cap of $19.61 million and a PE ratio of -1.64. The stock’s fifty day moving average price is A$0.39. Kazia Therapeutics Ltd has a 12-month low of A$0.32 ($0.23) and a 12-month high of A$0.60 ($0.43).
Kazia Therapeutics Company Profile
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops therapies for a range of oncology indications. Its lead product is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway that is in Phase II clinical trials to treat glioblastoma multiforme. The company is also developing TRX-E-002-1 (Cantrixil), a third-generation benzopyran molecule, which is in Phase I clinical trials to treat ovarian cancer.
Further Reading: What is a put option?
Receive News & Ratings for Kazia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kazia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.